Literature DB >> 10652433

Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells.

L Uhrbom1, G Hesselager, A Ostman, M Nistér, B Westermark.   

Abstract

In human gliomas, platelet-derived growth factor (PDGF) ligand and receptor mRNA are often co-expressed, which suggests the presence of an autocrine loop. To further investigate the significance of PDGF stimulation in brain tumors, we used a previously developed mouse tumor model, in which malignant brain tumors of neuroepithelial origin were induced by injecting a murine retrovirus containing the human PDGF B-chain gene into the brains of neonatal mice. In the present investigation, we have characterized a cell line established from such an experimentally induced tumor in an INK4a-/- mouse. Cultured tumor cells expressed nestin and NG2 chondroitin sulfate proteoglycan and are thus most likely derived from an oligodendrocyte precursor cell. Tumor cells produced PDGF-B protein and displayed constitutively activated PDGF alpha receptors. Autocrine receptor activation could be blocked with the specific PDGF receptor tyrosine kinase inhibitor CGP 57148B, which led to almost complete inhibition of cell proliferation, which was much less affected by a PDGF B-chain aptamer that inhibits binding of PDGF-B to PDGF receptors and is unlikely to be able to pass through the plasma membrane. Our results imply an important role for PDGF autocrine stimulation in both initiation and progression of a subtype of gliomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652433     DOI: 10.1002/(sici)1097-0215(20000201)85:3<398::aid-ijc17>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Roles of NG2 glial cells in diseases of the central nervous system.

Authors:  Jian-Ping Xu; Jie Zhao; Shao Li
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

Review 2.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

Review 3.  Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors.

Authors:  L Uhrbom; E C Holland
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

4.  Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.

Authors:  Janina Baranowska-Kortylewicz; Michio Abe; Kristian Pietras; Zbigniew P Kortylewicz; Takashi Kurizaki; Jessica Nearman; Janna Paulsson; R Lee Mosley; Charles A Enke; Arne Ostman
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 5.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

6.  Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells.

Authors:  Wiltrud Lederle; Hans-Jürgen Stark; Mihaela Skobe; Norbert E Fusenig; Margareta M Mueller
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

8.  PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2.

Authors:  Marta Terrile; Irene Appolloni; Filippo Calzolari; Roberto Perris; Evelina Tutucci; Paolo Malatesta
Journal:  BMC Cancer       Date:  2010-10-12       Impact factor: 4.430

Review 9.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

Review 10.  A role for the NG2 proteoglycan in glioma progression.

Authors:  William B Stallcup; Feng-Ju Huang
Journal:  Cell Adh Migr       Date:  2008-07-13       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.